الفهرس 
Sorafenib and radioembolizationOnly 14 pages are availabe for public view
 |  | from | 204 |  |  |
| | | from | 204 | | |
Abstract
Hepatocellular carcinoma (HCC) is the fifth most common form of cancer worldwide. In Egypt, it represents 75% of malignant liver tumors. Early detection and diagnosis of these cases is required for successful treatments and improved outcomes. Alpha-fetoprotein (AFP) is the most widely tested biomarker in HCC. However, its diagnostic value about early hepatocellular carcinomas remain controversial. Thus, it is necessary to identify new serologic biomarkers with both sufficient sensitivity and specificity to detect hepatocellular carcinomas at an early stage. Midkine, was identified as one of brthe important potential novel biomarkers for early detection of hepatocellular carcinomas. However, the diagnostic value of serum midkine for hepatocellular carcinomas, particularly for those with early stage, has not yet been investigated comprehensively. The present work was performed to study the utility of midkine as a diagnostic marker in patients with newly diagnosed hepatocellular carcinoma (HCC).